OUTCOME OF BOARD MEETING HELD ON 7TH FEBRUARY 2026 FOR APPROVAL OF UNAUDITED FINANCIAL STATEMENTS RESULTS FOR THE QUARTER ENDED ON 31ST DECEMBER 2025 AND OTHER MATTERS
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zenlabs Ethica's board approved its unaudited results for Q3 and nine months ended December 31, 2025. Revenue from operations fell to ₹1,242.78 lakh in Q3 from ₹1,272.29 lakh a year ago, and to ₹3,633.84 lakh for 9M FY26 from ₹3,843.71 lakh in 9M FY25, a decline of about 5.5%. The company reported a net loss of ₹200.76 lakh in Q3 and ₹193.67 lakh for 9M FY26, compared with profits of ₹8.51 lakh and ₹17.86 lakh respectively last year. The key reason is a ₹207.81 lakh exceptional write-off linked to the Reserve Bank of India cancelling the company's NBFC registration on November 7, 2025. The statutory auditor (N Kumar Chhabra & Co) issued an unmodified limited review opinion but specifically drew attention (emphasis of matter) to this RBI cancellation and business realignment. The board also appointed Mr. Amit Kumar as the new Company Secretary after Ms. Manju Bala resigned effective December 4, 2025.
Shareholders face a sharp swing to losses driven by the one-time NBFC-related write-off and weakening core trading margins in the pharma business. The cancellation of the NBFC licence is a major structural change, meaning future earnings depend entirely on how well the company can grow its pharmaceutical trading operations.